Unit

UNIT 4.18 Prostanoid Receptor Assays

  1. June Chen1,
  2. David F. Woodward1,
  3. Robert A. Coleman2,
  4. Robert L. Jones3,
  5. Simon J. Lydford4

Published Online: 1 NOV 2001

DOI: 10.1002/0471141755.ph0418s14

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Chen, J., Woodward, D. F., Coleman, R. A., Jones, R. L. and Lydford, S. J. 2001. Prostanoid Receptor Assays. Current Protocols in Pharmacology. 14:4.18:4.18.1–4.18.41.

Author Information

  1. 1

    Allergan, Irvine, California

  2. 2

    Pharmagene Laboratories Limited, Royston, United Kingdom

  3. 3

    The Chinese University of Hong Kong, Shatin, Hong Kong

  4. 4

    Molecular Devices Limited, Winnersh, United Kingdom

Publication History

  1. Published Online: 1 NOV 2001
  2. Published Print: SEP 2001

Abstract

Prostanoids, which include the prostaglandins (PGs) and thromboxanes (TXs), interact with a specific family of G-protein coupled receptors, of which there are known to be five distinct types, DP, EP, FP, IP and TP, each particularly sensitive to one of the five natural prostanoids, PGD2, PGE2, PGF2(, PGI2 and TXA2, respectively. Of these, it is known that the EP receptor comprises four well-characterized subtypes: EP1, EP2, EP3 and EP4. These receptor subtypes are widely distributed throughout mammals and other species, and show particularly high levels of expression in smooth muscle and blood platelets. Despite the fact that few of these preparations express a single receptor type/subtype in isolation, a range of useful smooth muscle and platelet assays for the various prostanoid receptors are available and are presented in this unit.